ULK1 and neoplasm: Soni et al. 38 demonstrated that in breast cancer cells, miR-489 could reduce tumor cell survival through inhibiting autophagy by targeting ULK1 and sensitizes tumor cells to doxorubicin via autophagy inhibition.